Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00646139 · ClinicalTrials.gov registry record · Phase 1
KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT00646139 is a Phase 1 study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 7 participants.
The verdict
NCT00646139, a Phase 1 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
RATIONALE: KX2-391 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of KX2-391 in treating patients with advanced solid tumors or lymphoma that did not respond to treatment.
Interventions
- OTHER pharmacological study
- OTHER immunoenzyme technique
- DRUG Src kinase inhibitor KX2-391
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2007-10 |
| Est. Completion | 2009-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00646139
The ClinicalTrials.gov registry entry for NCT00646139 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which pharmacological study is the first listed.
NCT00646139 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00646139 about?
NCT00646139 is a clinical study titled "KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment". RATIONALE: KX2-391 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of KX2-391 in treating patients with advanced solid tumors or lymphoma that did not respond to treatment.
What is the current status of trial NCT00646139?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2007-10. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00646139?
The interventions under investigation include: pharmacological study (OTHER), immunoenzyme technique (OTHER), Src kinase inhibitor KX2-391 (DRUG).
Who is sponsoring clinical trial NCT00646139?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.